Abstract Inhibition of Janus kinases [JAKs] in Crohn's disease [CD] patients has shown
conflicting results in clinical trials. Tofacitinib, a pan-JAK inhibitor, showed efficacy in …

Background: Treatment of inflammatory bowel diseases (IBD) has tremendously improved
during the last 20 years; however, a substantial fraction of patients does not respond to …

Introduction: New generations of small molecules are being developed for the treatment of
ulcerative colitis. Among them, tofatinib (a Janus kinase (JAK) inhibitor) has demonstrated …

Background Janus kinase (JAK) inhibitors represent a novel therapeutic class for treatment
of inflammatory bowel disease. Aims To determine the efficacy and safety of JAK inhibitors …

Early biologic therapy is recommended in patients with inflammatory bowel disease and
poor prognostic factors and in those refractory to conventional medications. Anti-tumor …

Background Ulcerative colitis is a chronic inflammatory disease of the colon for which
current treatments are not universally effective. One additional treatment may be tofacitinib …

Background & Aims Inhibitors of Janus kinases (JAKs) are being developed for treatment of
inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective …

The use of Janus kinase (JAK) inhibitors is a new approach in the therapy of inflammatory
diseases with immune base. Tofacitinib is one of these inhibitors targeting JAK1 and JAK3 …

Abstract Background and Aims Many inflammatory bowel disease (IBD) patients do not
respond to medical therapy. Tofacitinib is a first-in-class, partially selective inhibitor of Janus …

Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the
inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the …